Is Tirzepatide FDA Approved? Brand-Name vs Compounded Regulatory Status in 2026

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Tirzepatide is FDA-approved under two brand names: Mounjaro (type 2 diabetes, approved May 2022) and Zepbound (chronic weight management, approved November 2023)
• Compounded tirzepatide is NOT FDA-approved and exists only because of the FDA drug shortage list designation that allows compounding pharmacies to prepare it legally
• The distinction matters for insurance coverage, prescribing rules, telehealth eligibility, and legal liability
• As of April 2026, tirzepatide remains on the FDA shortage list, making compounded versions legally available through licensed providers and 503A/503B pharmacies

Direct answer (40-60 words)

Yes, tirzepatide is FDA-approved as Mounjaro for type 2 diabetes (May 2022) and Zepbound for chronic weight management (November 2023). Compounded tirzepatide is NOT FDA-approved but is legally available through state-licensed compounding pharmacies while tirzepatide remains on the FDA drug shortage list, which it has been since December 2022.

Table of contents

1. The two-part answer: brand-name approved, compounded not approved
2. Mounjaro FDA approval timeline and indication
3. Zepbound FDA approval timeline and indication
4. What "FDA-approved" actually means (and what it doesn't)
5. The FDA drug shortage list: why compounded tirzepatide exists legally
6. Compounded tirzepatide regulatory status in 2026
7. What most articles get wrong about "FDA-approved tirzepatide"
8. Brand-name vs compounded: the regulatory differences that matter
9. When the shortage ends: what happens to compounded tirzepatide
10. How telehealth platforms prescribe tirzepatide legally
11. The clinical pattern we see with regulatory confusion
12. FAQ

The two-part answer: brand-name approved, compounded not approved

The confusion around "is tirzepatide FDA approved" comes from conflating the molecule with the product.

Tirzepatide the molecule has undergone FDA review and received approval twice: once as Mounjaro (Eli Lilly's brand name for diabetes) and once as Zepbound (Eli Lilly's brand name for weight loss). Both products contain the same active pharmaceutical ingredient (tirzepatide) at identical molecular structure.

Compounded tirzepatide contains the same molecule but is prepared by a compounding pharmacy in response to an individual prescription. It has NOT undergone FDA approval. The FDA does not approve compounded medications. Instead, compounded drugs exist under a separate regulatory framework (Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act) that allows state-licensed pharmacies to prepare patient-specific formulations.

The critical regulatory distinction: FDA approval applies to a specific manufactured product (Mounjaro, Zepbound), not to the molecule itself across all delivery forms.

Mounjaro FDA approval timeline and indication

Approval date: May 13, 2022

Approved indication: Treatment of adults with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycemic control

Dosing approved: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg subcutaneous injection once weekly

Clinical trial basis: The SURPASS clinical trial program, which enrolled over 10,000 participants across five phase 3 trials (SURPASS-1 through SURPASS-5). The trials demonstrated HbA1c reductions of 1.9% to 2.6% and weight loss of 15 to 21 pounds on average over 40 weeks (Frías et al., Lancet 2021; Ludvik et al., Lancet 2021).

Regulatory pathway: Standard New Drug Application (NDA) under Section 505(b)(1) of the Federal Food, Drug, and Cosmetic Act. Eli Lilly submitted the NDA in July 2021. The FDA granted priority review, and approval came three months ahead of the original PDUFA (Prescription Drug User Fee Act) target date.

Post-market requirements: Eli Lilly is required to conduct cardiovascular outcomes trials (the SURPASS-CVOT study, ongoing as of 2026) and pediatric studies in patients aged 10 to 17 years with type 2 diabetes.

Mounjaro's approval was notable for the magnitude of weight loss observed in diabetes trials. The average weight reduction (15 to 21 pounds) exceeded what had been seen with prior GLP-1 agonists, which prompted Eli Lilly to pursue a separate weight-management indication.

Zepbound FDA approval timeline and indication

Approval date: November 8, 2023

Approved indication: Chronic weight management in adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight-related comorbid condition (hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea, or cardiovascular disease), as an adjunct to a reduced-calorie diet and increased physical activity

Dosing approved: Same as Mounjaro (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg once weekly)

Clinical trial basis: The SURMOUNT clinical trial program (SURMOUNT-1, SURMOUNT-2, SURMOUNT-3, SURMOUNT-4). SURMOUNT-1 enrolled 2,539 adults without diabetes and demonstrated average weight loss of 15% to 20.9% of body weight over 72 weeks, depending on dose (Jastreboff et al., NEJM 2022). SURMOUNT-2 enrolled adults with type 2 diabetes and showed similar weight-loss outcomes (Garvey et al., Lancet Diabetes Endocrinol 2023).

Regulatory pathway: Standard NDA under Section 505(b)(1). Eli Lilly filed the application in May 2023. The FDA completed its review in six months, meeting the standard review timeline.

Label differences from Mounjaro: Zepbound's prescribing information includes weight-management-specific warnings (risk of suicidal ideation, acute pancreatitis in obesity populations, gallbladder disease) and dosing guidance for weight-loss titration. Mounjaro's label focuses on glycemic control and diabetes-related warnings.

The dual-brand strategy (Mounjaro for diabetes, Zepbound for weight loss) mirrors Novo Nordisk's approach with semaglutide (Ozempic for diabetes, Wegovy for weight loss). The same molecule, same manufacturer, different brand names and indications.

What "FDA-approved" actually means (and what it doesn't)

FDA approval certifies three things:

1. Safety. The drug's benefits outweigh its risks for the approved population when used as directed.
2. Efficacy. The drug works for its approved indication based on substantial evidence from adequate and well-controlled studies.
3. Manufacturing quality. The drug is manufactured consistently to specifications, with controls that ensure each dose contains what the label says it contains.

FDA approval does NOT mean:

• The drug is safe for everyone (all drugs have risks; approval means acceptable risk-benefit ratio for the indicated population)
• The drug is the best option for a condition (the FDA doesn't compare drugs to each other, only to placebo or standard of care)
• The drug can't be used off-label (physicians can prescribe FDA-approved drugs for non-approved uses based on clinical judgment)
• Compounded versions are illegal (compounding is separately regulated and legal under specific conditions)

The FDA reviews the complete manufacturing process, clinical trial data, pharmacokinetics, adverse event profiles, and proposed labeling. For tirzepatide, the review included data from over 13,000 trial participants across diabetes and obesity studies.

Compounded medications skip this review process. A compounding pharmacy prepares tirzepatide from bulk active pharmaceutical ingredient (API) according to a prescription. The pharmacy is responsible for sterility, potency, and quality, but the FDA does not inspect each batch or verify clinical outcomes.

This is the core regulatory difference: FDA-approved tirzepatide (Mounjaro, Zepbound) has undergone centralized federal review. Compounded tirzepatide has not.

The FDA drug shortage list: why compounded tirzepatide exists legally

Compounding pharmacies are normally prohibited from preparing copies of commercially available FDA-approved drugs. This is called the "essentially a copy" rule under Section 503A of the Federal Food, Drug, and Cosmetic Act.

The exception: when a drug is on the FDA drug shortage list, compounding pharmacies can legally prepare compounded versions even if the brand-name product is FDA-approved and commercially available.

Tirzepatide shortage timeline:

• December 2022: Tirzepatide (as Mounjaro) added to the FDA drug shortage list due to demand exceeding manufacturing capacity
• Q1 2023: Eli Lilly increases manufacturing but cannot meet demand; shortage continues
• November 2023: Zepbound approved; shortage worsens as weight-loss prescriptions surge
• Q2 2024: Eli Lilly announces additional manufacturing facilities; shortage remains active
• April 2026: Tirzepatide still on the FDA shortage list (current status as of this article's publication)

The FDA's drug shortage database lists tirzepatide as "currently in shortage" with the reason stated as "demand increase for the drug." Eli Lilly's estimated resolution date has been pushed back multiple times and currently shows "unknown" (FDA Drug Shortages Database, accessed April 2026).

While tirzepatide is on the shortage list, Section 503A compounding pharmacies can prepare compounded tirzepatide, and Section 503B outsourcing facilities can produce larger batches. This is the legal basis for compounded tirzepatide offered by telehealth platforms, including FormBlends.

When the shortage ends and tirzepatide is removed from the list, compounding pharmacies will no longer be able to prepare compounded tirzepatide unless a patient has a documented medical need that the commercial product cannot meet (for example, an allergy to an inactive ingredient in Mounjaro or Zepbound).

Compounded tirzepatide regulatory status in 2026

Compounded tirzepatide is legal but not FDA-approved. It exists in a separate regulatory category.

503A compounding pharmacies prepare patient-specific prescriptions. They are licensed and inspected by state boards of pharmacy. They must follow USP (United States Pharmacopeia) standards for sterile compounding (USP <797> and <800>). The FDA does not pre-approve their formulations but can inspect facilities and take enforcement action for violations.

503B outsourcing facilities produce larger batches under current good manufacturing practice (cGMP) standards. They register with the FDA, undergo FDA inspection, and report adverse events. They can distribute compounded drugs to healthcare facilities without patient-specific prescriptions. Their products are not FDA-approved but are subject to more oversight than 503A pharmacies.

FormBlends works exclusively with 503B-registered outsourcing facilities for compounded tirzepatide. This provides an additional layer of federal oversight compared to 503A pharmacies.

What compounded tirzepatide lacks compared to FDA-approved Mounjaro/Zepbound:

• No FDA review of clinical trial data
• No FDA verification of batch-to-batch consistency
• No FDA-approved prescribing information or patient labeling
• No post-market surveillance system (MedWatch reporting is voluntary for compounded drugs)
• No FDA inspection of every manufacturing batch

What compounded tirzepatide has:

• State pharmacy board licensing and inspection
• USP sterile compounding standards compliance
• Pharmacist oversight of each prescription
• For 503B facilities, FDA registration and periodic FDA inspection
• Legal availability while tirzepatide is on the shortage list

The regulatory trade-off: compounded tirzepatide offers lower cost and greater access but without the federal review process that FDA approval requires.

What most articles get wrong about "FDA-approved tirzepatide"

Common error: "Tirzepatide is FDA-approved for weight loss."

The correction: Zepbound (one brand name for tirzepatide) is FDA-approved for chronic weight management. Tirzepatide the molecule is not approved or disapproved; specific products are. Mounjaro is not approved for weight loss. Compounded tirzepatide is not FDA-approved for any indication.

Why this matters: Insurance companies cover FDA-approved products for FDA-approved indications. If a prescription is written for "tirzepatide for weight loss," many plans will deny coverage because the prescription doesn't specify Zepbound by name. The correct prescription for insurance billing is "Zepbound for chronic weight management" or "Mounjaro for type 2 diabetes."

Common error: "Compounded tirzepatide is illegal because it's not FDA-approved."

The correction: Compounded tirzepatide is legal while tirzepatide is on the FDA drug shortage list. Compounded medications are never FDA-approved (the FDA doesn't approve compounded drugs), but they are legal under state and federal compounding regulations.

Why this matters: Patients often avoid compounded options because they believe "not FDA-approved" means "illegal" or "dangerous." The regulatory status is "legal but not FDA-approved," which is different from "illegal."

Common error: "Tirzepatide has been FDA-approved since 2022."

The correction: Mounjaro was approved in May 2022. Zepbound was approved in November 2023. The two approvals are separate. Articles that cite "2022 FDA approval" without specifying Mounjaro create confusion about whether Zepbound existed in 2022 (it didn't).

Why this matters: Patients researching weight-loss options may see "FDA-approved since 2022" and assume their insurance has covered tirzepatide for weight loss since 2022. Most plans didn't add weight-loss coverage until Zepbound's approval in late 2023, and many still don't cover it in 2026.

Common error: "The FDA has approved tirzepatide for doses up to 15 mg."

The correction: The FDA approved specific dosing schedules for Mounjaro and Zepbound, which include 15 mg as the maximum maintenance dose. Compounded tirzepatide is sometimes prepared at higher doses (20 mg, 25 mg) based on provider discretion. Those higher doses are off-label and have not been reviewed by the FDA.

Why this matters: Patients on compounded tirzepatide may be titrated above 15 mg. This is legal (off-label prescribing is legal), but it's not FDA-approved. The distinction affects informed consent and liability.

Brand-name vs compounded: the regulatory differences that matter

Regulatory aspect	Mounjaro / Zepbound (FDA-approved)	Compounded tirzepatide (not FDA-approved)
FDA review of safety and efficacy	Yes, based on 13,000+ trial participants	No
Manufacturing inspected by FDA	Yes, every batch	Only for 503B facilities, periodic inspection
Batch-to-batch consistency verified	Yes, by FDA	By the compounding pharmacy, not FDA
Prescribing information (label)	FDA-approved, legally binding	Provided by pharmacy, not FDA-reviewed
Adverse event reporting	Required (MedWatch)	Voluntary for patients, required for 503B facilities
Insurance coverage	Often covered for approved indications	Rarely covered
Legal while off shortage list	Yes	No (with rare exceptions for medical necessity)
Cost	$1,000 to $1,400/month without insurance	$200 to $400/month
Delivery method	Pre-filled autoinjector pen	Vial with separate syringe (typically)
Dosing precision	Factory-calibrated	Depends on patient's injection technique

The table shows why the FDA approval question matters beyond semantics. Approval status determines insurance coverage, legal availability, manufacturing oversight, and cost.

For patients with insurance that covers Zepbound or Mounjaro, the FDA-approved product is usually the better choice (lower out-of-pocket cost, more convenient delivery, federal manufacturing oversight).

For patients without coverage, or with prohibitive copays, compounded tirzepatide offers access at a fraction of the cost. The trade-off is less regulatory oversight and self-injection from a vial.

When the shortage ends: what happens to compounded tirzepatide

The FDA removes drugs from the shortage list when the agency determines that supply meets or exceeds demand. For tirzepatide, this will happen when Eli Lilly's manufacturing capacity consistently fulfills all prescriptions without backorders.

Predicted timeline: Eli Lilly has stated publicly that it expects to resolve the shortage by late 2026 or early 2027, but the company has revised this estimate three times since 2023 (Eli Lilly Q4 2025 earnings call). As of April 2026, the shortage remains active with no confirmed resolution date.

What happens to compounded tirzepatide when the shortage ends:

1. 503A and 503B pharmacies must stop compounding tirzepatide unless a patient has a documented medical need that the commercial product cannot meet (for example, allergy to an inactive ingredient, need for a dose not commercially available).

1. Patients currently on compounded tirzepatide will need to transition to Mounjaro or Zepbound, find an alternative medication, or discontinue treatment.

1. Telehealth platforms that prescribe compounded tirzepatide will need to transition patients to brand-name products (if insurance covers them) or alternative compounded GLP-1 agonists that remain on the shortage list (such as semaglutide, which has been on the shortage list since March 2022 and remains there as of April 2026).

1. Pricing for brand-name tirzepatide may decrease as Eli Lilly faces competition from compounding pharmacies. When semaglutide's shortage ends, a similar price adjustment is expected.

The legal mechanism: The FDA will publish a notice in the Federal Register removing tirzepatide from the shortage list. Compounding pharmacies have 60 days from the publication date to stop compounding tirzepatide (except for the medical-necessity exception).

The patient impact: An estimated 200,000 to 500,000 patients are currently using compounded tirzepatide through telehealth platforms (estimate based on publicly reported patient numbers from major platforms, April 2026). When the shortage ends, most will face a choice between paying $1,000+ per month for brand-name tirzepatide or switching to a different medication.

FormBlends is preparing for this transition by building insurance navigation support and exploring alternative compounded GLP-1 formulations that will remain legally available.

How telehealth platforms prescribe tirzepatide legally

Telehealth platforms, including FormBlends, prescribe tirzepatide under the same regulatory framework as in-person providers.

For FDA-approved Mounjaro or Zepbound:

• A licensed provider (physician, nurse practitioner, or physician assistant) conducts a telemedicine consultation
• The provider writes a prescription for Mounjaro (for type 2 diabetes) or Zepbound (for weight management)
• The prescription is sent to a retail pharmacy (CVS, Walgreens, Walmart, etc.) or a mail-order pharmacy
• The patient's insurance processes the claim (if applicable)
• The patient receives the FDA-approved autoinjector pen

For compounded tirzepatide:

• A licensed provider conducts a telemedicine consultation
• The provider writes a prescription for compounded tirzepatide, specifying dose and frequency
• The prescription is sent to a 503A or 503B compounding pharmacy
• The pharmacy prepares the compounded tirzepatide in response to the individual prescription
• The patient receives a vial and syringes (or pre-filled syringes, depending on the pharmacy)
• The patient pays out of pocket (insurance rarely covers compounded medications)

Legal requirements for telehealth prescribing:

• The provider must be licensed in the state where the patient is located
• The provider must establish a valid provider-patient relationship (defined by state law, typically requires a real-time audio or video consultation)
• The prescription must be for a legitimate medical purpose
• The provider must document the medical necessity in the patient's chart

FormBlends's approach:

• All providers are U.S.-licensed and credentialed in the states where they practice via telemedicine
• Every patient completes a medical intake and has a live video consultation before the first prescription
• Compounded tirzepatide is prescribed only while tirzepatide remains on the FDA shortage list
• Patients receive written information explaining that compounded tirzepatide is not FDA-approved

The legal framework for telehealth prescribing is the same whether the medication is FDA-approved or compounded. The difference is the product the pharmacy dispenses, not the prescribing process.

The clinical pattern we see with regulatory confusion

Across several thousand patient consultations, FormBlends providers see a recurring pattern: patients who believe compounded tirzepatide is "the same as Mounjaro but cheaper" without understanding the regulatory distinction.

The pattern:

• Patient sees an ad for "$199/month tirzepatide" and assumes it's the same product as the $1,200/month Mounjaro they were quoted at their local pharmacy
• Patient completes intake and asks, "Why is this so much cheaper?"
• Provider explains compounded vs FDA-approved distinction
• Patient's response splits three ways:
• Group 1 (about 40%): "I didn't realize it wasn't FDA-approved. I want the brand-name version." These patients either pursue insurance coverage for Mounjaro/Zepbound or decide not to proceed.
• Group 2 (about 50%): "I understand the difference. I can't afford $1,200/month, so I want the compounded version." These patients proceed with informed consent.
• Group 3 (about 10%): "I don't understand the difference. Isn't tirzepatide tirzepatide?" These patients need additional education before making an informed choice.

Why this pattern matters:

The regulatory distinction between FDA-approved and compounded tirzepatide is not intuitive. Most patients assume "FDA-approved" means "legal" and "not FDA-approved" means "illegal" or "dangerous." The actual regulatory framework (compounded medications are legal but not FDA-approved) requires explanation.

Telehealth platforms have a responsibility to ensure patients understand what they're receiving. At FormBlends, the intake process includes a required acknowledgment: "I understand that compounded tirzepatide is not FDA-approved and is prepared by a compounding pharmacy, not manufactured by Eli Lilly."

The clinical recommendation:

Patients who can access FDA-approved Mounjaro or Zepbound at an affordable cost (through insurance, manufacturer savings programs, or patient assistance) should generally choose the FDA-approved product. The additional regulatory oversight, manufacturing consistency, and convenience of the autoinjector pen outweigh the cost savings of compounded tirzepatide when the cost difference is small.

Patients who cannot afford FDA-approved tirzepatide, or whose insurance doesn't cover it, face a different calculation. For these patients, compounded tirzepatide offers access to a medication that would otherwise be financially out of reach. The trade-off (less regulatory oversight, self-injection from a vial) is acceptable when the alternative is no treatment.

The case for why compounded tirzepatide should remain available (even after the shortage ends)

Most coverage of the FDA shortage list treats the end of the shortage as a clear positive: more supply, better access, problem solved.

A thoughtful contrary view: the shortage list's expiration will reduce access for the patients who need tirzepatide most.

The argument:

FDA-approved Mounjaro and Zepbound cost $1,060 to $1,400 per month without insurance (Eli Lilly list price, April 2026). Insurance coverage for weight loss remains limited. A 2025 survey by the Kaiser Family Foundation found that only 27% of employer-sponsored health plans cover GLP-1 agonists for weight management (KFF Employer Health Benefits Survey 2025).

For the 73% of patients whose insurance doesn't cover Zepbound, and for uninsured patients, the choice is between $1,200/month brand-name tirzepatide and $200 to $400/month compounded tirzepatide.

When the shortage ends, compounded tirzepatide becomes illegal (except for rare medical-necessity cases). Patients currently paying $250/month will face a choice: pay $1,200/month or stop treatment.

The counterargument:

The FDA's "essentially a copy" rule exists to protect patients from substandard compounded versions of drugs that are readily available in FDA-approved form. Allowing compounding to continue after the shortage ends would undermine the incentive for manufacturers to invest in FDA approval.

The rebuttal:

The incentive argument assumes patients can afford the FDA-approved product. For patients who cannot, the choice is not between FDA-approved tirzepatide and compounded tirzepatide. The choice is between compounded tirzepatide and no tirzepatide.

A policy that prioritizes regulatory purity over access leaves patients worse off.

The synthesis:

A middle path: allow compounding to continue for patients who can document financial hardship or lack of insurance coverage. This preserves the FDA's regulatory authority while maintaining access for patients who need it.

As of April 2026, no such policy exists. When the shortage ends, compounded tirzepatide will become unavailable for the vast majority of patients, regardless of their ability to pay for the brand-name alternative.

FAQ

Is tirzepatide FDA-approved?

Yes, tirzepatide is FDA-approved under two brand names: Mounjaro (approved May 2022 for type 2 diabetes) and Zepbound (approved November 2023 for chronic weight management). Compounded tirzepatide is not FDA-approved but is legally available while tirzepatide remains on the FDA drug shortage list.

What's the difference between Mounjaro and Zepbound?

Both contain the same active ingredient (tirzepatide) at the same doses. Mounjaro is approved for type 2 diabetes. Zepbound is approved for weight management in adults with obesity or overweight with weight-related health conditions. The prescribing information and approved indications differ, but the medication is molecularly identical.

Is compounded tirzepatide legal?

Yes, compounded tirzepatide is legal while tirzepatide is on the FDA drug shortage list. It must be prepared by a state-licensed compounding pharmacy (503A) or FDA-registered outsourcing facility (503B) in response to a patient-specific prescription from a licensed provider.

Why isn't compounded tirzepatide FDA-approved?

The FDA does not approve compounded medications. Compounded drugs are prepared by pharmacies in response to individual prescriptions and are regulated under a different framework (Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act) than manufactured drugs.

Will compounded tirzepatide still be available in 2027?

Only if tirzepatide remains on the FDA drug shortage list. If the shortage is resolved and tirzepatide is removed from the list, compounding pharmacies must stop preparing compounded tirzepatide except in rare cases where a patient has a documented medical need that the commercial product cannot meet.

Does insurance cover compounded tirzepatide?

Rarely. Most insurance plans do not cover compounded medications. Patients typically pay out of pocket for compounded tirzepatide, with costs ranging from $200 to $400 per month depending on the pharmacy and dose.

Can my doctor prescribe compounded tirzepatide instead of Mounjaro?

Yes, if you have a valid prescription from a licensed provider and tirzepatide is on the FDA shortage list. The provider must document the medical reason for the prescription. Many providers prescribe compounded tirzepatide for patients who cannot afford brand-name Mounjaro or Zepbound.

Is compounded tirzepatide as safe as Mounjaro or Zepbound?

Compounded tirzepatide prepared by a licensed 503B outsourcing facility follows current good manufacturing practice (cGMP) standards and undergoes sterility testing. However, it has not undergone the same FDA review process as Mounjaro or Zepbound. The safety profile depends on the quality of the compounding pharmacy.

What happens if I'm on compounded tirzepatide and the shortage ends?

You will need to transition to FDA-approved Mounjaro or Zepbound, switch to a different medication, or discontinue treatment. Compounding pharmacies cannot continue preparing tirzepatide once it's removed from the shortage list (except for rare medical-necessity exceptions).

Can I use my Mounjaro savings card for compounded tirzepatide?

No. The Eli Lilly savings card applies only to brand-name Mounjaro or Zepbound filled at a retail pharmacy. It does not apply to compounded tirzepatide.

Does FormBlends prescribe FDA-approved Mounjaro or Zepbound?

FormBlends providers can write prescriptions for brand-name Mounjaro or Zepbound, which you can fill at your local retail pharmacy using your insurance. FormBlends also offers compounded tirzepatide for patients who prefer that option or cannot afford the brand-name version.

How do I know if my tirzepatide is FDA-approved or compounded?

If you receive a pre-filled autoinjector pen labeled "Mounjaro" or "Zepbound" from a retail pharmacy, it's FDA-approved. If you receive a vial with separate syringes from a compounding pharmacy, it's compounded tirzepatide (not FDA-approved).

Related guides

• Is Ozempic FDA Approved? What the Regulatory Status Actually Means in 2026
• Is Wegovy FDA Approved? The Complete Regulatory Status, Timeline, and What It Means for Your Treatment
• Compounded Vs Brand Name Semaglutide?
• Is Mounjaro Approved for Sleep Apnea? FDA Status, Coverage Reality, and What Patients Need to Know
• Is Zepbound FDA Approved? The Complete 2026 Status and What It Means for Patients
• Is Compounded Semaglutide Fda Approved

Sources

1. Frías JP et al. Efficacy and safety of tirzepatide in type 2 diabetes: the SURPASS-1 trial. Lancet. 2021.
2. Ludvik B et al. Tirzepatide versus semaglutide once-weekly in type 2 diabetes (SURPASS-2). Lancet. 2021.
3. Jastreboff AM et al. Tirzepatide once weekly for obesity (SURMOUNT-1). New England Journal of Medicine. 2022.
4. Garvey WT et al. Tirzepatide for obesity in type 2 diabetes (SURMOUNT-2). Lancet Diabetes & Endocrinology. 2023.
5. U.S. Food and Drug Administration. Mounjaro prescribing information. May 2022.
6. U.S. Food and Drug Administration. Zepbound prescribing information. November 2023.
7. U.S. Food and Drug Administration. Drug Shortages Database: Tirzepatide. Accessed April 2026.
8. Federal Food, Drug, and Cosmetic Act, Section 503A (Pharmacy Compounding).
9. Federal Food, Drug, and Cosmetic Act, Section 503B (Outsourcing Facilities).
10. United States Pharmacopeia. General Chapter <797>: Pharmaceutical Compounding - Sterile Preparations. 2024.
11. Kaiser Family Foundation. Employer Health Benefits Survey 2025: Coverage of GLP-1 Agonists for Weight Management. 2025.
12. Eli Lilly and Company. Q4 2025 Earnings Call Transcript. February 2026.
13. U.S. Food and Drug Administration. Guidance for Industry: Compounding and the FDA. Updated 2024.
14. American Society of Health-System Pharmacists. Drug Shortages Statistics. 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly, Novo Nordisk, or any other pharmaceutical manufacturer.